美银证券:重申信达生物(01810)“买入”评级 上调目标价至61.1港元

金融界
Apr 25, 2025

智通财经APP获悉,美银证券发布研报称,基于主要产品强劲销售,上调信达生物(01810)今明两年销售预测1%,把目标价从52港元上调至61.1港元,重申“买入”评级,基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币,同比升47.6%及32.3%,达伯华销售同比升15.4%至5,150万元人民币。同时,睿妥及Tafolecimab销售分别同比...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10